Navigation Links
BridgePoint Medical Announced 510(k) Clearance for an Expanded Indication to Treat Coronary Chronic Total Occlusions
Date:5/16/2011

MINNEAPOLIS, May 16, 2011 /PRNewswire/ -- BridgePoint Medical, Inc., a Minnesota-based medical device company, has announced that they have received clearance of an expanded indication for the CrossBoss™ Catheter and Stingray™ System from the FDA.  The expanded indication includes the intraluminal placement of conventional guidewires beyond stenotic coronary lesions [including chronic total occlusions (CTOs)] prior to PTCA or stent intervention.  CTOs are chronically stenosed lesions that completely block a coronary artery – typically for 3 months or longer - and prevent blood circulation to critical areas of the heart.  

Company Founder & COO Chad Kugler reflected, "This is the culmination of 5 years of development, clinical and regulatory work.  We are grateful for the opportunity to market these products for the specific challenge they were developed for and confident that we have created a great solution for treating CTOs."

This expanded indication is the result of data generated from the 147-patient FAST-CTOs clinical trial in which the safety and effectiveness of the system in coronary chronic total occlusions was demonstrated.

Dr. William Lombardi of St. Joseph's Hospital in Bellingham, WA and a leading enroller in the clinical trial states, "The BridgePoint system is the first set of devices designed specifically for treating coronary Chronic Total Occlusions that has shown real improvements in safety, procedural efficiency, and clinical success rates.  The clinical trial has proven that these arteries can be opened effectively with these products and now with the expanded indication from the FDA there will be a new level of awareness among physicians and patients."

BridgePoint's ability to commercialize its CrossBoss™ Catheter and Stingray™ System will be greatly expanded with this new level of indication.  BridgePoint is the first interventional device company to be granted this specific type of approval for both crossing and re-entry technologies to be used in the treatment of coronary CTOs.

Company CEO and President Denis Harrington says, "We are excited about the expanded indication.  The FAST-CTO Trial demonstrated the safety and effectiveness of the CrossBoss Catheter and Stingray System in treating these most challenging lesions – CTOs.  And we are poised to be the leader in helping physicians treat these patients."

About BridgePoint Medical:

BridgePoint Medical, Inc. is a privately held company established in 2006 to design, develop and commercialize new technologies and techniques to treat challenging coronary and peripheral artery disease.  Investors include New Enterprise Associates, Polaris Venture Partners, Foundation Medical Partners and Michael Berman.


'/>"/>
SOURCE BridgePoint Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BridgePoint Medical Names Industry Veteran as Chief Executive Officer
2. BridgePoint Medical Closes $9.1 Million Series C Financing
3. BridgePoint Medical®, Inc. Completes and Submits to FDA in the U.S. FAST-CTOs With the CrossBoss® and Stingray® CTO Recanalization System
4. BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries
5. UBM Canon Medical Device Content Team Announces Upcoming Virtual Event Content Topics
6. FDA Formally Accepts Dune Medicals MarginProbe™ System Pre-Market Approval (PMA) Application and Grants Expedited Review Status
7. STMicroelectronics Reveals Best-in-Class Technology Enabling Longer-Lasting Broadcast and Medical-Imaging Equipment
8. Reportlinker Adds Impact of Healthcare Reforms on the Medical Technology Industry
9. Winner Medical to Present at Oppenheimer 5th Annual China Dragon Conference
10. Royce Receives Coveted Medical Products Award
11. Medical Care Technologies Inc. Selects Geographical Location for Flagship Childrens Health Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):